

Expression from herpesvirus promoters does not relieve the intron requirement for cytoplasmic accumulation of human β -globin mRNA

Xian-ming Yu⁺, Gregory W. Gelembiuk, Chung-Yih Wang[§], Wang-Shick Ryu[†] and Janet E. Mertz*
McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI 53706, USA

ABSTRACT

Expression plasmids were constructed in which the human β -globin gene or a variant of it precisely lacking its two introns was transcribed from its own promoter, the herpes simplex virus type 1 thymidine kinase (HSV-tk) promoter, or the immediate early promoter of human cytomegalovirus (CMV-IE). Forty two hours after transfection of these plasmids into monkey kidney cells, nuclear and cytoplasmic RNA were isolated. Quantitative S1 nuclease mapping and primer extension analysis were used to determine the relative abundances, cellular locations, and leader sizes of the accumulated β -globin RNAs. Whereas transcripts of all of the intron-containing genes accumulated in the cytoplasm to high levels, transcripts of their cDNA variants were neither stably maintained in the nucleus nor accumulated in the cytoplasm, irrespective of the promoter from which transcription was driven. We conclude that the intron requirement for cytoplasmic accumulation of β -globin RNA can not be circumvented by synthesis from either the promoter of the intronless HSV-tk gene or the CMV-IE promoter.

INTRODUCTION

Most genes in higher eukaryotes contain introns. Whereas many of these genes require introns for efficient expression, some do not. For example, the naturally intronless herpes simplex virus type 1 thymidine kinase (HSV-tk) gene is expressed efficiently regardless of the presence of introns (1,2). Efficient expression of some genes is intron dependent because transcriptional enhancer elements are encoded within the introns. However, the intron dependence of at least some genes (e.g. 's, SV40 late, β -globin) is post-transcriptional in nature [see (2,3) and references cited therein].

Two reports have appeared recently indicating that expression from certain herpesvirus promoters (e.g. 's, cytomegalovirus immediate early (CMV-IE), HSV-tk) can overcome the intron requirement of at least some genes (e.g. 's, immunoglobulin, β -globin) for proper processing and nuclear export of their transcripts (1,4). However, CMV transcripts synthesized from

the IE promoter in its natural context do not accumulate as unspliced mRNAs; rather, multiple alternatively spliced introns are excised from them. We show here that synthesis from the CMV-IE promoter does not obviate the intron dependence of β -globin. Furthermore, during the course of followup experiments designed to map the *cis*-acting element(s) within the HSV-tk promoter responsible for intron independence, we discovered that these elements mapped entirely upstream of the HSV-tk promoter sequences (5), leading us to propose an alternative explanation for the cytoplasmic accumulation of RNA synthesized from our intronless constructs. As we show here, what appeared in our case to be intron-independent accumulation of β -globin transcripts synthesized from the HSV-tk promoter (1) was, in actuality, efficient accumulation of transcripts initiated at upstream sequences within the plasmid.

MATERIALS AND METHODS

Plasmids

All plasmids were constructed by standard recombinant DNA techniques (6). The starting plasmid, p β - β IVS(+), has been described in detail elsewhere (1,7). It contains the nt 812 to nt +2156 (relative to the site of transcription initiation) region of the human β -globin gene in an SV40 ori-containing, pBR322-based vector (Fig. 1). Plasmid p β - β IVS(–) is identical in sequence to p β - β IVS(+) except for the precise lack of the two β -globin introns. It was constructed by recombination of p β - β IVS(+) with a plasmid containing a cDNA version of the human β -globin gene. The promoter region of pSVTK- β IVS(+) (Fig. 1) was obtained from plasmid pDG013 (8), a gift from D. Greenspan. It contains the enhancer region of SV40 inserted into a KpnI site located upstream of the HSV-tk promoter of HSV-1 strain CL101. The novel HSV-tk/ β -globin joint was constructed by cutting the β -globin DNA with NcoI, filling in the NcoI site, adding BglII linker DNA (CAGAT-CTG), cleaving with BglII, and ligating to BglII-cut HSV-tk DNA. Plasmid pTK- β IVS(+) (Fig. 1) was constructed from pSVTK- β IVS(+) by excision of the SV40 enhancer region fragment with PvuII. The promoter region of pCMV- β IVS(+) was taken from the HCMV-IE1 gene (approximately nt –1200 to nt –17 relative to the start site of transcription). The distal (HindIII-to-NcoI) and

* To whom correspondence should be addressed

Present addresses: ⁺Shanghai Institute of Biochemistry, Academia Sinica, Shanghai, China, [§]Howard Hughes Medical Institute, University of Michigan, Medical Center, Ann Arbor, MI and [†]Fox Chase Cancer Center, Institute for Cancer Research, Philadelphia, PA, USA

proximal (NcoI-to-AluI) fragments of this segment were obtained, respectively, from pHCMV- $\nu\mu$ [In1] (4) and pCATwt760 (9), regenerating the intact pHCMV-IE1 promoter region. Nt -9 to +53 of the human β -globin gene was replaced by the homologous segment of the mouse major β -globin gene taken from pMH β SV-330 LS21/10, a linker scanning mutant in which a BgIII linker is substituted for nt -21 to -10 [an additional 12 bp linker is present at nt +28] (10). The CMV/ β -globin joint was constructed by cutting pMH β SV-330 LS-21/-10 with BgIII, filling in the BgIII end, and ligating to AluI-cut HCMV DNA. Plasmids p β -IVS(-), pCMV- β IVS(-), pTK- β IVS(-), and pSVTK- β IVS(-) are identical in sequence to plasmids p β -IVS(+), pCMV- β IVS(+), pTK- β IVS(+), and pSVTK- β IVS(+), respectively, except for their precise lack of the two β -globin introns. The origin of pRSV-Tori is described elsewhere (1,7).

Transfections and RNA analyses

In all experiments, the intron dependence of gene expression was tested by co-transfection of the African green monkey kidney cell line, CV-1PD, with 2 μ g of test plasmid DNA and 1 μ g of pRSV-Tori per 100 mm dish of cells by the DEAE-dextran followed by chlorquine method as described previously (3). Cells were harvested 42 h after transfection and fractionated into nuclear and cytoplasmic components by treatment with 0.5% Nonidet P40 as described previously (3). Nuclear and cytoplasmic RNAs were purified as described previously (3). Cellular β -actin RNA served as an internal control for recovery of the RNA samples and purity of the nuclear RNA. Southern blot analysis,

performed as described elsewhere (1,7), of the relative amounts of DpnI-resistant, β -globin-encoding plasmid DNA present in each nucleic acid sample prior to treatment with DNase I was used to assay both (i) for nuclear contamination of cytoplasmic nucleic acid and (ii) for differences in transfection efficiencies. The latter were found to vary by at most two fold within an experiment (data not shown).

Quantitative S1 nuclease mapping analysis was performed by the trichloroacetic acid method of Murray (11). The probes used are shown in Figures 2B and 2C. Primer extension analysis was done as described by Good (12) with a 5' end-labeled nt +90 to nt +114 (relative to the β -globin site of transcription initiation) antisense synthetic oligonucleotide serving as primer. In brief, RNA was mixed with 2×10^6 cpm of 5' end-labeled primer and 20 μ g carrier poly(A) (Pharmacia) in 10 μ l of 0.3 M NaCl, 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, denatured at 80° for 5 min, and annealed at 65° for 30 min. The primer was extended by the addition of 5 units of AMV reverse transcriptase (Life Sciences, Inc.), 20 units of RNasin (Promega), and 40 μ l reverse transcriptase buffer [12.5 mM Tris-HCl (pH 8.4), 12.5 mM DTT, 1.25 mM each of dGTP, dCTP, dATP, and TTP, 62.5 μ g/ml actinomycin D, and 15 mM MgCl₂] and incubation at 48° for 2 h. The reaction was terminated and RNA was hydrolyzed by addition of 6 μ l 1M NaOH and 1 μ l 0.5 M EDTA, incubation at 60° for 1 h, then neutralization with HCl. The resulting DNAs were precipitated with ethanol, resuspended in 80% formamide, 10 mM NaOH, 1 mM EDTA, and electrophoresed in an 8M urea, 6% polyacrylamide gel.




Figure 1. Structures of the plasmids used in this study. Only the regions of each plasmid involved in synthesis of β -globin RNA are shown. The numbers above each line are the nucleotide residues relative to the major transcription initiation site indicated by the rightward arrow. The polyadenylation signal is indicated by AAUAAA. The vectors are not shown. The construction of the p β -IVS(+) vector is described in detail elsewhere (1,7). It contains the following sequences: the enhancer region of SV40 (SV40 nt 38 through 299); a spacer consisting of HSV-1 DNA nt -510 to -722 relative to the transcription initiation site of the TK gene; a minimal origin of SV40 DNA replication (SV40 nt 5171 to 34 plus nt 198 to 272, inclusive); the Ball-to-EcoRI region of the poison-minus derivative of pBR322, pAT153 (14); and a spacer consisting of SV40 nt 2297 to 2533. The vectors in the other plasmids are the same as the one in p β -IVS(+) except for the deletion of SV40 nt 38 through 269 from pTK- β IVS(+) and pTK- β IVS(-), the precise deletion of the HSV spacer and SV40 enhancer regions in pCMV- β IVS(+) and pCMV- β IVS(-), pTK- β IVS(-), and pSVTK- β IVS(+). The plasmids p β -IVS(-), pCMV- β IVS(-), pTK- β IVS(-), and pSVTK- β IVS(-) are identical in sequence to their corresponding IVS(+) counterparts except for the precise lack of IVS1 and IVS2. Crosshatched boxes, human β -globin promoter, exon, and 3' region sequences; open boxes, human β -globin intron sequences; horizontally striped box, mouse β -globin sequence; hatched boxes, herpesvirus promoter region sequences; stippled box, SV40 promoter region sequence. Restriction sites inactivated during construction of the plasmids are in parentheses. Abbreviations: A, ApaLI; Al, AluI; B, BamHI; Bg, BglIII; H, HindIII; Hc, HincII; IVS, intervening sequence; K, KpnI; M, MspI; Nc, NcoI; P, PvuII.

having been synthesized from the β -globin and HSV-tk promoters, respectively (Fig. 3, lanes 4 and 16, respectively). On the other hand, the leaders of the β -globin RNAs accumulated in the pSVTK- β IVS(-)-transfected cells were quite heterogeneous in size (Fig. 3, lane 18). Most of the accumulated β -globin RNA had been synthesized from upstream promoters rather than from the HSV-tk promoter. Noteworthy is the fact that the transcripts initiated from the HSV-tk TATA box (indicated by the arrow adjacent to lane 15 of Fig. 3) failed to accumulate, while most of those initiated from other sites accumulated to similar levels whether or not the β -globin introns were present (Fig. 3, lane 16 vs. 18). Therefore, synthesis from the HSV-tk promoter does not relieve, even partially, intron dependence of β -globin RNA accumulation. Our finding that initiation from other, upstream promoters appears to do so may be a consequence of these β -globin transcripts possessing additional sequences at their 5' ends that (i) enable cryptic splicing out of introns and/or (ii) contain elements specifying intron independence analogous to those present within the coding region of the HSV-tk gene (1,2,7).

In an attempt to eliminate readthrough transcription from upstream promoters, we deleted from pSVTK- β IVS(+) and pSVTK- β IVS(-) the non-essential SV40 enhancer region present within the vector. The accumulation of β -globin RNA synthesized from the resulting plasmids, pTK- β IVS(+) and pTK- β IVS(-), was analyzed as above. Cytoplasmic accumulation of β -globin RNA was largely intron dependent, with these RNAs having 5' ends that mapped to the HSV-tk promoter (Fig. 2A, lane 12 vs. 14; Fig. 3, lane 12 vs. 14). Furthermore, insertion of this SV40 enhancer-containing restriction fragment into p β - β IVS(-) at nt -266 (relative to the authentic transcription initiation site) resulted in high levels of readthrough transcription, partially restoring RNA accumulation in the absence of the two natural β -globin introns (5). These results clearly establish that synthesis from the HSV-tk promoter does not supplant the intron requirement for cytoplasmic accumulation of β -globin mRNA.

Synthesis from CMV-IE promoter also does not relieve intron dependence

Neuberger and Williams (4) have published data indicating that the intron dependent, cytoplasmic accumulation of immunoglobulin μ RNA is overcome in J558L plasmacytoma cells by synthesis from the CMV-IE or *Drosophila hps70* heat-shock promoter. If their finding is generalizable, one would predict that synthesis from the CMV-IE promoter would also relieve intron dependence of β -globin RNA accumulation in CV1-PD cells. To test this prediction, we constructed the plasmid pCMV- β IVS(+) (Fig. 1) and its intronless counterpart, pCMV- β IVS(-). Analysis as above of the β -globin RNA accumulated in cells transfected with these plasmids indicated that β -globin RNA accumulation was still highly intron dependent (Figs. 2A and 3, lanes 7–10). Therefore, synthesis from the CMV-IE promoter does not alleviate β -globin's intron requirement for cytoplasmic accumulation in CV1-PD cells.

DISCUSSION

In the study presented here, we have shown clearly that the very strong intron dependence for cytoplasmic accumulation of human β -globin RNA (Figs. 2A and 3, lanes 3–6) cannot be overcome by synthesis from the HSV-tk promoter (Figs. 2A and 3, lanes 11–18). Our previous data indicating that synthesis from

the HSV-tk promoter might at least partially relieve intron dependence (1) was herein shown to be the result of readthrough transcription from upstream promoters (Fig. 3, lanes 15–18). These findings are consistent with those of Buchman and Berg (2) who reported that the presence of the rabbit β -globin second intron increased 20 fold cytoplasmic accumulation of a rabbit β -globin-like RNA synthesized from the HSV-tk promoter. Extending this conclusion, we have found that synthesis from the CMV-IE promoter also can not overcome this intron dependence for β -globin RNA accumulation (Figs. 2A and 3, lane 7–10).

On the other hand, Neuberger and Williams (4) have reported that the intron requirement for immunoglobulin μ expression can be obviated by synthesis from the CMV-IE promoter. The reason for the discrepancy between their and our findings is not clear. Differences between their and our experiments included their use of (i) a different test gene, (ii) expression from an integrated state, and (iii) plasmacytoma instead of monkey kidney cells. Which, if any, of these differences accounts for the CMV-IE promoter conferring intron independent expression in their case, but not ours, remains to be determined. The finding of Arrigo and Chen (13) that Rev is required for cytoplasmic localization of HIV-1 *env/vpu2* RNA in COS, but not lymphoid cells, indicates that cell line differences may underlie this seeming discrepancy.

In summary, the findings presented here demonstrate that synthesis from promoters of intronless genes does not in general overcome the need of some transcripts to contain introns. Remaining to be answered is whether there exist any RNAs with a clear post-transcriptional intron requirement for cytoplasmic accumulation whose intron requirement can be overcome by synthesis from a particular promoter under all conditions.

ACKNOWLEDGEMENTS

Dedicated to Paul Berg on the occasion of his 65th birthday. We thank Patrick Charnay, Dan Greenspan, Steve McKnight, and Michael Neuberger for gifts of plasmids and Paul Lambert and members of our laboratory for discussions and helpful comments on the manuscript. This research was supported by U.S. Public Health Service grants CA-07175 and CA22443 from the National Cancer Institute.

REFERENCES

1. Ryu, W.-S. (1989) Ph.D. thesis, University of Wisconsin, Madison, WI.
2. Buchman, A. R. and Berg, P. (1988) *Mol. Cell. Biol.*, **8**, 4395–4405.
3. Ryu, W.-S. and Mertz, J. E. (1989) *J. Virol.*, **63**, 4386–4394.
4. Neuberger, M. S. and Williams, G. T. (1988) *Nucleic Acids Res.*, **16**, 6713–6724.
5. Wang, C.-Y. and Mertz, J. E. (unpublished).
6. Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) *Molecular Cloning, A Laboratory Manual*, Second edition, Cold Spring Harbor Laboratory.
7. Ryu, W.-S., Gelembiuk, G. W. and Mertz, J. E. (manuscript in preparation).
8. Greenspan, D. S. and Weissman, S. M. (1985) *Mol. Cell. Biol.*, **5**, 1894–1900.
9. Stinski, M. F. and Roehr, T. J. (1985) *J. Virol.*, **55**, 431–441.
10. Charnay, P., Mellon, P. and Maniatis, T. (1985) *Mol. Cell. Biol.*, **5**, 1498–1511.
11. Murray, M. G. (1986) *Anal. Biochem.*, **158**, 165–170.
12. Good, P. J. (1987) Ph.D. thesis, University of Wisconsin, Madison, WI.
13. Arrigo, S. J. and Chen, I. S. Y. (1991) *Gene Dev.*, **5**, 808–819.
14. Twigg, A. J. and Sherratt, D. (1980) *Nature*, **283**, 216–218.
15. Sedman, S. A., Good, P. J. and Mertz, J. E. (1989) *J. Virol.*, **63**, 3884–3893.